AstraZeneca slammed by advocacy group over drug discount denials

AstraZeneca decided it will begin denying the discounts it offers under the federal 340B drug pricing program to on-site hospital pharmacies on Oct. 1, according to a statement from the British drugmaker.

The Aug. 17 statement did not disclose the reason for the upcoming discount denials, but detailed that all 340B pricing for on-site hospital pharmacies will be honored through Sept. 30.

The following day, drug pricing organization 340B Health issued a statement on AstraZeneca's decision to deny 340B discounts to on-site hospital pharmacies